News Release Details
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
Data Published Online in
The study describes an improved synthesis of a heroin-like molecule (a hapten) that is an essential component of OPNT005, which would make it practical to scale the synthesis of this molecule for clinical use. Additionally, OPNT005 produced high levels of antibodies in rodents. These antibodies cross react with heroin and other abused opioids, including oxycodone and hydrocodone. The pharmacological effects of intravenous heroin were significantly diminished in rodents receiving OPNT005.
“We are highly encouraged by these compelling pre-clinical results,” said
OPNT005 was developed jointly by the
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
LifeSci Advisors, LLC
Source: Opiant Pharmaceuticals, Inc.